Market Place
Sourcing Support
Ex-Theseus execs extend GIST mission by taking helm of IDRx
12 Mar 2024 //
ENDPTS
Theseus Pharmaceuticals Announces Closing of Tender Offer
14 Feb 2024 //
PR NEWSWIRE
Concentra scores another win as Theseus agrees to buyout offer
21 Dec 2023 //
FIERCE BIOTECH
Theseus Confirms Receipt of Expression of Interest from Foresite Capital
27 Nov 2023 //
PR NEWSWIRE
Months after ending cancer program, Theseus lays off 72%
15 Nov 2023 //
FIERCE BIOTECH
Theseus Pharmaceuticals Announces Process to Explore Strategic Alternatives
13 Nov 2023 //
PRESS RELEASE
Theseus Pharmaceuticals to Participate in the Stifel 2023 Healthcare Conference
07 Nov 2023 //
PR NEWSWIRE
Theseus to Discontinue Enrollment in Ph 1/2 & Terminate Development of THE-630
13 Jul 2023 //
PR NEWSWIRE
Theseus Reports Initial Dose Escalation Data from Phase 1/2 Trial of THE-630
25 May 2023 //
PR NEWSWIRE
Theseus Pharmaceuticals Announces Business Highlights and Reports 1Q 2023 FYR
11 May 2023 //
PR NEWSWIRE
Theseus Initial Dose Escalation Results from Ongoing Ph 1/2 Trial of THE-630
26 Apr 2023 //
PR NEWSWIRE
Theseus Pharmaceuticals to Participate in Upcoming Investor Conferences
11 Apr 2023 //
PR NEWSWIRE
Theseus to Participate in the Cantor Future of Oncology Virtual Symposium
28 Mar 2023 //
PR NEWSWIRE
Theseus Pharma Reports Fourth Quarter and Full Year 2022 Financial Results
09 Mar 2023 //
PR NEWSWIRE
Theseus to Participate in the SVB Securities Global Biopharma Conference
07 Feb 2023 //
PRESS RELEASE
Theseus Announces BCR-ABL as Target for Third Development Program
05 Jan 2023 //
PRESS RELEASE
Theseus Announces Business and Reports Third Quarter 2022 Financial Results
03 Jan 2023 //
PRESS RELEASE
Theseus Pharmaceuticals Reports Third Quarter 2022 Financial Results
03 Nov 2022 //
PRESS RELEASE
Theseus Pharmaceuticals Presents Preclinical Data Characterizing THE-349
26 Oct 2022 //
PRNEWSWIRE
Theseus Pharmaceuticals Appoints Steven Stein, M.D. to Board of Directors
19 Oct 2022 //
PRNEWSWIRE
Theseus Pharmaceuticals Nominates THE-349
03 Oct 2022 //
PRNEWSWIRE
Theseus Pharma to Participate at Upcoming September Investor Conferences
06 Sep 2022 //
PRNEWSWIRE
Theseus Pharma to Participate Virtually in Wedbush PacGrow Healthcare Conference
03 Aug 2022 //
PRNEWSWIRE
Theseus Pharmaceuticals to Participate in Upcoming Investor Conferences
19 May 2022 //
PRNEWSWIRE
Theseus Pharmaceuticals Appoints Don Hayden to Board of Directors
18 May 2022 //
PRNEWSWIRE
Theseus Pharma Reports First Quarter 2022 Financial Results
12 May 2022 //
PRNEWSWIRE
Theseus Pharma Announces PC Data on EGFR Inhibitors at the 2022 AACR
08 Apr 2022 //
PRNEWSWIRE
Theseus Pharma to Participate Virtually in Needham Healthcare Conference
05 Apr 2022 //
PRNEWSWIRE
Vipergen Establishes DEL-Based Drug Discovery Partnership with Theseus Pharma
04 Apr 2022 //
PRNEWSWIRE
Theseus Pharma Reports Fourth Quarter and Full Year 2021 Financial Results
10 Mar 2022 //
PRNEWSWIRE
Theseus Pharma to Present PC Data on Next-Gen EGFR Inhibitors at 2022 AACR
08 Mar 2022 //
PRNEWSWIRE
Theseus Pharma Receives U.S. FDA ODD for THE-630 for Advanced GIST
02 Feb 2022 //
PRNEWSWIRE
Theseus Pharma Treats First Patient with THE-630 in Phase 1/2 Study in GIST
10 Jan 2022 //
PRNEWSWIRE
Theseus Pharma Appoints Alicja Januszewicz as Senior Vice President
16 Dec 2021 //
PRESS RELEASE
Theseus Announces Business Highlights and Reports Q3 2021 Financial Results
15 Nov 2021 //
PRNEWSWIRE
Theseus Announces FDA Clearance of INDA for THE-630
01 Nov 2021 //
PRNEWSWIRE
Theseus stock pops 53% intraday following cancer-drug firm’s upsized IPO
07 Oct 2021 //
SEEKINGALPHA
OrbiMed`s TKI play makes its Nasdaq debut as Theseus prices IPO
07 Oct 2021 //
ENDPTS
Theseus Pharmaceuticals Announces Pricing of Initial Public Offering
06 Oct 2021 //
PRNEWSWIRE
Solid tumor biotech Theseus Pharmaceuticals files for a $100 million IPO
15 Sep 2021 //
RENAISSANCECAPITAL
Theseus Appoints Kathy Yi to Board of Directors and Chair of Audit Committee
10 Jun 2021 //
PRNEWSWIRE
